Ngo L Y, Yogev R, Dankner W M, Hughes W T, Burchett S, Xu J, Sadler B, Unadkat J D
Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, USA.
Antimicrob Agents Chemother. 1999 Jun;43(6):1516-9. doi: 10.1128/AAC.43.6.1516.
To evaluate if atovaquone (ATQ) interacts pharmacokinetically with azithromycin (AZ) in human immunodeficiency virus-infected children, 10 subjects (ages, 4 to 13 years) were randomized in a crossover study to receive AZ (5 mg/kg/day) alone (ALONE) or AZ (5 mg/kg/day) and ATQ (30 mg/kg/day) simultaneously (SIM) prior to receiving AZ and ATQ staggered by 12 h. Despite a lack of significant difference in the mean AZ pharmacokinetic parameters, the steady-state values of AZ's area under the concentration-time curve from 0 to 24 h and maximum concentration in serum were consistently lower (n = 7 of 7) for the SIM regimen than they were for the ALONE regimen. A larger study will be required to determine if ATQ affects AZ pharmacokinetics and efficacy in a clinically significant manner.
为评估阿托伐醌（ATQ）与阿奇霉素（AZ）在感染人类免疫缺陷病毒的儿童体内是否存在药代动力学相互作用，10名受试者（年龄4至13岁）参与了一项交叉研究，随机分组后，在接受AZ（5mg/kg/天）和ATQ（30mg/kg/天）错开12小时给药之前，分别单独接受AZ（5mg/kg/天）（单独给药组）或同时接受AZ（5mg/kg/天）和ATQ（30mg/kg/天）（联合给药组）。尽管AZ的平均药代动力学参数无显著差异，但联合给药组0至24小时的浓度-时间曲线下面积及血清中的最大浓度的稳态值始终低于单独给药组（7例中有7例）。需要开展更大规模的研究，以确定ATQ是否会以具有临床意义的方式影响AZ的药代动力学和疗效。
